Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Intrathecal MSCs in ALS
NCT04821479Phase 2Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Jan 2016
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Hadassah Medical Organization. Primary endpoints: Adverse Events at 18 months and Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 18 months. Started Jan 2016; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04821479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821479.